drugset / Trial / NCT06048107

Teniposide Incorporating Bu/Cy Conditioning Regimen for HLH With Central Nervous System Involvemen

NCT06048107

Unknown 20 enrolled Beijing Friendship Hospital
NaSingle-groupOpen-labelTreatment

Summary

Hemophagocytic lymphohistiocytosis (HLH) is a highly inflammatory disease involving cytokine storms and is characterised by rapid progression and high mortality. There are no uniform clinical criteria for the diagnosis of CNS-HLH.And there is still a lack of international consensus on the treatment for CNS-HLH. Following allogeneic HSCT after HLH induction therapy is recommended for CNS-HLH. One of the major factors influencing the transplantation effect is conditioning. Therefore, we conduct a prospective clinical study to explore the efficacy and safety of Teniposide incorporating Bu/Cy conditioning regimen followed by allogeneic hematopoietic stem cell transplantation for HLH with central nervous system involvement.

Timeline

Start
2023-10-22
Primary completion
2024-09-30
Completion
2025-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Teniposide Small molecule